



CannaVerde
Pharma

Fully Licensed Producer Serving the Latin American Medical Cannabis Market

INVESTOR PRESENTATION
November 2020



DISCLAIMER

An investment in CannaVerde Pharma (“the Company”) is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing entire investment.

Forward-Looking Statements: Statements contained in this presentation that are not historical facts are forward-looking information that involves known and unknown risks and uncertainties. Forward looking statements in this presentation can be identified by the use of words such as “plans”, “proposed”, “has proven”, “expects” or “does not expect”, “is expected”, “upside”, “potential”, “appears”, “budget”, “scheduled”, “estimates”, “forecasts”, “goal”, “at least”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will be taken”, “occur” or “be achieved”.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the assumptions and risks associated with associated approval of license applications in Colombia for cultivation, production and export; generating and finalizing contractual arrangements on terms favorable to the Company or at all; the ability to achieve product milestones in order to satisfy customer demands and deliveries prior to the execution of definitive customer contracts; market acceptance and adoption of the Company’s business plan and the ability to specifically tailor the Company’s platform to meet the demands of prospective customers; forecast of number of product lines and sales; commencement of new operations and plans for expansion; the inability for the Company to execute its corporate strategy as described in this Presentation or at all; commodity prices; changes in general economic conditions; market sentiment; currency exchange rates; the Company’s ability to continue as a going concern; the Company’s ability to raise funds through equity financings; risks inherent in cannabis sector; risks related to operations in foreign countries; failure of equipment or processes to operate as anticipated; accidents, labor disputes, security and other risks; delays in obtaining governmental approvals for importation of product to anticipated markets; and government legalization of recreational use in anticipated markets.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, do not place undue reliance on forward-looking statements. All statements are made as of the date of this presentation and the Company is under no obligation to update or alter any forward-looking statements. This Presentation contains financial outlook information regarding the Company’s prospective revenue and EBITDA, which is subject to the same assumptions, risk factors, limitations, and qualifications as set forth above. Revenue and EBITDA estimates contained in this Presentation were made by management as of the date of this Presentation and are provided to demonstrate the anticipated market penetration and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that this information may not be appropriate for any other purpose and readers should not place undue reliance on such financial outlooks. The Company’s actual revenue and EBITDA may differ materially from management’s current expectations. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual results of operations.

The information contained in this presentation has been furnished or supplied by the Company based on the most accurate information available as at the date hereof and there is no representation or warranty by Industrial Alliance Securities Inc. and, if applicable on behalf of a syndicate of agents, as to the accuracy or completeness of such information.

U.S. Securities Laws: This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company’s shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.



STRATEGIC VISION: LATIN AMERICA

Our vision is to become the **leading medical cannabis company** in Colombia and throughout Latin America

Latin America's population of approx. 640 million is nearly twice that of the U.S.; medical cannabis is legal in >75% of Latin America (see map); multi billion-dollar market is projected

In the Consumer Products and Wellness category, **CannaVerde** is partnering with major CPG manufacturers to penetrate the USD \$8.5 billion market in Colombia

“Global spending on legal cannabis is forecast to reach USD \$31.4 billion by 2021”

Source: Brightfield Group

Note: The Latin America Regional Cannabis Report: 2019 Industry Outlook, estimates the total addressable cannabis market (regulated and illicit) at USD \$9.8 billion






DEMAND FOR MEDICAL CANNABIS

68 million qualifying patients in Latin America

Medical cannabis is legal in Colombia, Chile, Peru, Uruguay, Brazil, Mexico, Argentina (**>75% of population of Latin America**) - *Source: Brightfield Group*





COLOMBIA'S REGULATORY ROADMAP

Step 1: Apply for three licenses - The licenses are for the 1) cultivation of high-THC cannabis, 2) cultivation of low-THC cannabis, 3) extraction/manufacturing and 4) seed/genetics distribution

Step 2: Receive licenses

Step 3: Receive “scientific” quota - After proving security controls and health and safety standards, the producer receives a “scientific” quota from the Ministry of Health to grow mother plants for testing, development and research

Step 4: Register genetics - Register as agronomical unit with Colombian Agricultural Institute (ICA) and submit strains for registration. (Deadline was 12/31/18)

Step 5: Test genetics - Mature plants tested by ICA who then issue final approval. Producer can begin commercial production of low-THC strains; apply for high-THC quota

Step 6: Receive high-THC quota - Grower allowed to plant a specific # of high-THC plants

Step 7: ICA evaluation - Agronomical evaluation process by Ministry of Agriculture and Colombian Agricultural Institute (ICA)



Regulatory approval process in Colombia is complex and time-consuming. **CannaVerde** is one of the few cannabis companies that has successfully navigated **all mandatory steps** and has been fully approved to commercially cultivate, extract, and sell cannabis extracts in Colombia as well as export abroad.



ABOUT US

CannaVerde Pharma is a Canadian-domiciled, low-cost, high quality producer of medical cannabis extracts with operations in Colombia through its wholly owned subsidiary, **Green Health Colombia**.

Green Health holds licenses to cultivate, extract, manufacture, domestically distribute and export CBD (cannabidiol) and THC (tetrahydrocannabinol) medical extracts.

Furthermore, Green Health has registered eight strains with varying CBD, THC and CBG profiles with the Colombian Agricultural Institute and can now begin commercial cultivation. The company has nearly completed registration of 57 additional strains with various THC profiles.

IDEAL SITE LOCATION

- 7 licensed hectares (option to additional 100 hectares)
- Access to natural water reservoirs and minimal energy costs
- Strong technical workforce

MASSIVE GROWING POTENTIAL

- Built 51,000 sq. ft. of greenhouse space
 - Two greenhouses = 21,160 sq. ft.
 - 1/2 of 60,000 sq. ft. greenhouse completed

ATTRACTIVE REGULATORY ENVIRONMENT

- Government mandate to become world's largest producer and exporter of cannabis derivatives

OPTIMAL GROWING CONDITIONS

- Warm weather, 12 hours of light per day
- Up to six cultivations per year
- Abundant natural water supply and excellent soil quality

ACCESS TO LARGE MARKET

- Access to 640 million people throughout Latin America



GREEN HEALTH COLOMBIA: IN PICTURES

Green Health has established a fully-licensed cannabis operation in Mesa de Los Santos, Colombia. The operation can be scaled to 415,000 sq. ft. of cultivation space to yield 6.6 million grams of **cannabis oil** (CBD, THC) annually.





MANAGEMENT TEAM

CannaVerde's outstanding management team is led by CEO Michael Nistorescu, a seasoned financial and strategic executive, and is comprised of medical doctors, scientists, engineers, and operational experts with 56 years combined experience.



MICHAEL NISTORESCU, Chief Executive Officer

Mr. Nistorescu began his career as a financial analyst at Gluskin Sheff + Associates before being appointed Investments Director at Infinite Potential Management (Blackberry founders). He then co-founded a cannabis-focused private equity firm where he served as CEO and Investments Director. Mr. Nistorescu is a CFA charterholder and holds a BA in Economics from York University.



IVAN OSSMA, MD, Chief Medical Officer

Dr. Ossma graduated as a medical doctor from Pontificia Universidad Javeriana and obtained a Masters in Public Health from Johns Hopkins University and a Masters in Science from Harvard T.H. Chan School of Public Health. He has served as an advisory board member for Abbott Laboratories and Novartis and has been involved in numerous FDA monitored clinical trials.



EDUARDO MAYORGA, President

Mr. Mayorga is the founder of Green Health Colombia and has over nineteen years experience in the strategic management, planning and development of projects throughout Colombia, which include Bogota Free Trade Zone, MOS Bank, CCND El Dorado Airport, and BP Oil and Gas. He holds an MBA from U Externado.



PAUL ROBERTSON, Chief Financial Officer

Mr. Robertson is a Chartered Professional Accountant with extensive experience in the mining sector in Colombia. Mr. Robertson was previously the CFO of Grayd Resource Corporation (acquired by Agnico Eagle). He holds a BA from the University of Western Ontario.



SHANE WHELAN-STUBBS, Director, Cultivation

Mr. Whelan-Stubbs was a co-founder of a Canadian licensed producer. He has been involved in all aspects of cannabis cultivation. Mr. Whelan-Stubbs has achieved yields north of 120 grams per sq. ft. He brings tremendous experience in cultivation, nutrient formulation, soil composition and strain selection.



DR. PETER CHEN, Chief Science Officer

Dr. Chen holds a PhD in Food Science from the University of Guelph where he was the recipient of the Governor General's Academic Gold Medal for academic excellence. He has experience working as Lead Scientist and VP of Science for two licensed cannabis producers in Canada.



ADVISORY BOARD

CARLOS ULLOA

Dr. Ulloa is a medical doctor specializing in sports medicine with more than 10 years experience caring for the well-being of performance athletes in Colombia. Dr. Ulloa graduated from the Pontificia Universidad Javeriana and the Universidad Del Bosque. Dr. Ulloa served in the position of team physician for Colombia's National Soccer team for the past 10 years. He also served as the team physician for the Olympic Team, FEDETENIS and CONMEBOL.

JAVIER PATINO

Mr. Patiño is an Industrial Engineer with more than 38 years of experience in the Fast-Moving Consumer Goods companies in Latin America. As a General Manager, Mr. Patiño has worked for both Yanbal and Quaker Oats. During his 5-year career at Yanbal, Mr. Patiño achieved an increase in revenues from USD \$50 million to over USD \$200 million. He has participated in over 150 new product launches throughout Latin America. He graduated from the Universidad de Los Andes (Colombia) and from the Wharton Business School.

LUIS VILLEGAS

Dr. Villegas has worked as an anesthesiologist specializing in acute and chronic pain management for over 15 years. Dr. Villegas is a founder of one of the most recognized ophthalmology clinics in Medellin, Colombia. He graduated from the U.P.B. School of Medicine and from the Universidad del Valle in Cali. He earned his MBA from EAFIT University in Medellin. Since 2014, Dr. Villegas has served as the President of OCCULUS Corp., a company focused on commercializing medical tourism to Latin America.






RESEARCH AND DEVELOPMENT

Our Chief Medical Officer, Dr. **Ivan Ossma** and his wife, Dr. **Andrea Galvis**, have been instrumental in developing our strategy for the medical sector. Their work in establishing clinical research partnerships with **FOSCAL** hospital will serve to help us better design products for oncologic pain relief. Additionally, work is being done to finalize a collaborative basic science and applied research partnership with a medical school and university hospital in western Colombia to accelerate proof of concept for commercial application in the fields of neurology, dermatology, and pain medicine.

FOSCAL is one of the largest tertiary care centers in Colombia, comprised of 410 hospital beds, 350 medical specialists, and 300 medical consultants located in the department of Santander. Their services include multi-tissue bench and Center for advanced therapies, oncology, ophthalmology and medical checkups, among others.



MEDICAL CANNABIS CLUSTER IN SANTANDER



CO-DEVELOPMENT & SALES AGREEMENT: Salud Dar

Salud Dar is a provider of health services in alternative medicine. Its main activity are the promotion of health, the prevention of diseases, and the development of medicine that targets a wide range of ailments.

Medical Precision Care is an INVIMA-registered master pharmacy and is in the process of obtaining an extension to include medicinal cannabis.

Green Health Colombia has partnered with Salud Dar and Medical Precision Care to:

1. Develop magistral formulas that contain CBD and THC for sale in pharmacies throughout Colombia
2. Research and develop new products that can be prescribed by doctors through existing pharmacy networks



SaludDar
Somos Salud

Medicina
Alternativa y
Complementaria



medical
precision care
Medicina de Cannabis personalizada de Precisión



Green Health
C O L O M B I A

CO-DEVELOPMENT AGREEMENT: JGB

JGB S.A. is a consumer packaged goods company with more than 1,000 employees producing oral care, personal care, home care, and supplements distributed throughout Colombia and Latin America. Green Health Colombia has partnered with JGB to:

1. Integrate CBD into existing product lines
2. Develop new product lines containing CBD, with JGB assuming product development, manufacturing, marketing and retail distribution



Green Health
Colombia



CO-DEVELOPMENT AGREEMENT: PROMY

Promy is a consumer packaged goods company with a focus on the manufacture and marketing of cosmetic products and toiletries, as well as the development of customized products to the requirements of clients. Green Health Colombia has partnered with Promy to:

1. Integrate CBD into existing product lines
2. Develop new product lines containing CBD, with Promy assuming product development, manufacturing, marketing and retail distribution



Green Health
C o l o m b i a

DISTRIBUTION AGREEMENT: FARANDA HOTELS & RESORTS

Faranda Hotels and Resorts is a hotel group with properties in Spain, Colombia, Panama, Mexico, Dominican Republic, and Venezuela.

Green Health Colombia has partnered with Faranda Hotels to:

1. Place CBD-based products as toiletries in hotel rooms.
The pilot program will focus on Hotel Casa La Factoria and Hotel Bantu in Cartagena
2. Develop new product lines containing CBD and distribute them in hotels throughout Latin America





FLOWER & OIL SALES STRATEGY

Go-to-Market Plan

- Establish joint venture agreements with Latin American consumer product manufacturers
- Partner with doctors to distribute cannabis extract formulations in Colombia
- Partner with pharmacies/clinics to leverage existing sales channels
- Supply agreements with Latin American, Canadian, European importers

STATUS OF CONTRACTS AND LETTERS OF INTENT

CBD Distillate / Isolate: 6 domestic and 1 for export

	Status	Size of Order (CBD)	Timing	Notes
1	Definitive signed	\$3,250,000	Q3/Q4	Up to 500 kgs of cannabis distillate
2	LOI Signed	\$60,000	end Q2	Initial order for product testing
3	LOI signed	TBD	end Q2	Initial order for product testing
4	LOI Signed	TBD	end Q2	Working through export/import paperwork
5	LOI Signed	TBD	end Q2	Colombian beauty company; present in 30 countries/51 stores in Colombia
6	LOI Signed	TBD	end Q2	Colombian cosmetic company; currently importing CBD from Italy
7	LOI Signed	\$30,000	end Q2	Initial order for product testing; Hotel Line of CBD products



*All figures in CAD



CAPITAL STRUCTURE

Capital Structure (Oct 2020)	
Shares outstanding	12,117,677
Price per share	CAD \$0.60
Valuation	CAD \$7,270,606
Debentures	3,080,000
Warrants	88,300
Issued & Outstanding (fully diluted)	17,339,310



CAPITAL RAISE – TERMS & USE OF PROCEEDS

TERMS

- Seeking a minimum of CAD **\$5,000,000** and a maximum of CAD **\$10,000,000**.
- Convertible **unsecured 2-year debentures** yielding 10% (in shares) per annum payable at the earlier of IPO or maturity date; mandatory conversion into common shares at CAD \$0.60 upon IPO or maturity
- **CAD \$5.2 million** has been invested to date
- Minimum investment amount of CAD \$5,000

USE OF PROCEEDS

- Complete scientific evaluation with the Colombian Agricultural Institute
- Develop proprietary medical products for Latin American market
- Assist doctors and clinics with prescriptions of cannabis-based medication
- Construct greenhouses
- Complete GMP-compliant extraction facility
- Complete JV agreements to produce CBD wellness products
- Sales and marketing
- Operating expenses





CannaVerde
Pharma

PARTNER WITH US

Michael Nistorescu, CEO, CannaVerde Pharma

michael@cannaverdepharma.com | 416.882.9006

Paul Robertson, CFO, CannaVerde Pharma

paul@cannaverdepharma.com | 778.227.0071

www.cannaverdepharma.com